Navigation Links
New TUMS(R) QuikPak(TM) Campaign Offers Innovative Heartburn Relief with a Little Help from the Jetsons
Date:4/21/2008

First of Its Kind Instant Dissolve Powder Antacid Delivers Faster Relief,

Increased Convenience and Great Taste

PITTSBURGH, April 21 /PRNewswire/ -- Today, GlaxoSmithKline (GSK) Consumer Healthcare launches a $20 million integrated marketing campaign for the new TUMS(R) QuikPak(TM), the first and only instant dissolve antacid powder, from the trusted TUMS brand. The QuikPak campaign, part of a larger new "Bring It On" brand strategy designed to re-energize the classic TUMS brand with fresh imagery and broader appeal, features the classic animated series, "The Jetsons."

"In this campaign, two icons -- TUMS and the Jetsons -- meet to tell the story about a fast and convenient heartburn medicine getting even faster with new TUMS QuikPak," says Sydney R. Rollock, GSK Consumer Healthcare vice president of Health and Wellness. "What better way to tell the product innovation story than by linking up with a classic cartoon that represents speed and innovation?"

In a :30 spot airing on national network and cable television beginning today, April 21, George Jetson suffers heartburn after enjoying a chili dog with the works, and calls out for his wife by screaming, "JaaaAANE!". Before she can get to him, though, Rosie the Robot opens his mouth, pours in a dose from a packet of TUMS QuikPak, and he experiences fast relief. The spot closes with the family dog Astro singing, "Ruff, ruff, ruff, ruff, RUFF!," to the tune of the classic TUMS jingle.

The TUMS "Bring It On" brand strategy succeeds the TUMS "Diner" brand campaign, which ran for more than 30 years. According to Rollock, it was time for TUMS advertising to evolve along with the product innovation.

"With the introduction of TUMS QuikPak our goal was to create advertising more representative of the brand's iconic nature," he explains. "The 'Jetsons' is also iconic and a beloved, animated family we all grew up with in the 60's, 70's and 80's.

TUMS QuikPak, a
'/>"/>

SOURCE GlaxoSmithKline Consumer Healthcare
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioSpace and BayBio Launch 11th Edition of Biotech Bay(TM) Hotbed Map Campaign
2. BioSpace, 2008 BIO International Convention and BIOCOM Launch 9th Edition of Biotech Beach Hotbed Map Campaign
3. Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Televisions 13th Annual Multi-Platform Stop Breast Cancer For Life Campaign
4. Homewatch CareGivers Launches 2007 We Care For Veterans Campaign
5. Move to AMITIZA Advertising Campaign Underscores the Power of Not Letting Chronic Constipation Slow People Down
6. Natural Nutrition Launches International Marketing Campaign for New All Natural Analgesic: BLUE LIGHTNING(TM) Fast Pain Relief
7. BioSpace Launches 2nd Edition of Southern Pharm(TM) Hotbed Campaign
8. BioSpace Launches 3rd Edition of BioForest(TM) Bioscience Marketing Campaign
9. DeviceSpace.com Launches Marketing Campaign for US Medical Device Industry
10. BioSpace and the Massachusetts Biotechnology Council Launch 2008 Genetown(TM) Hotbed Campaign
11. Organogenesis Debuts Educational Campaign for Sufferers of Chronic Leg and Foot Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
Other Biology Technology:Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 2Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 3Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 4Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 5Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 6Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 7Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 8Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 9Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 10Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 11Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 12Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 13Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 14Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 15Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 16Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 17Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 18Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 19Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 20Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 21Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 22Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 23Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 24Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 25Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 26Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 27Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 2Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 3Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 4Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 5Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 6Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 7Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 8Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 9Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 10